Treatment of Hairy Cell Leukemia in its Second Half-Century

April 26–27, 2010

Wilson Hall (Building 1), 3rd Floor
National Institutes of Health, Bethesda, MD

Sponsored by the
National Cancer Institute
NIH Office of Rare Diseases Research
Hairy Cell Leukemia Consortium

For more information or to register, please visit
http://web.ncifcrf.gov/events/leukemia/default.asp
Treatment of Hairy Cell Leukemia in its Second Half-Century

Meeting Chair: Robert J. Kreitman, MD
Sponsored by the National Cancer Institute, NIH Office of Rare Diseases Research, and Hairy Cell Leukemia Consortium
April 26-27, 2010
Wilson Hall (Building 1), 3rd floor, NIH, Bethesda, Maryland

Monday, April 26, 2010

7:15 Registration and Continental Breakfast
8:00 Introductory Comments
   Robert J. Kreitman, MD
8:05 Hairy Cell Leukemia (HCL): 50 Years of History
   Harvey Golomb, MD

Diagnosis of HCL
8:20 Elaine Jaffe, MD: Diagnosis by morphology including differential diagnosis
8:35 Maryalice Stetler-Stevenson, MD, PhD: Diagnosis by flow cytometry
8:50 Estella Matutes, MD, PhD: Differential diagnosis of HCL with HCL-variant and typical and diffuse red pulp SMZL

9:05 Brunangelo Falini, MD: The nature of the hairy cell
9:20 Aaron Polliack, MD: Surface topography of HCL cells and other leukemias - as seen by SEM
9:30 Discussion

Historical Treatments of HCL
9:40 Kanti Rai, MD: Splenectomy and interferon, past and current uses

Treatment of HCL with Pentostatin
10:00 Anthony Ho, MD, PhD: Results of pentostatin in HCL compared to other B- & T-cell malignancies
10:15 Claire Dearden, MD: Long term results of pentostatin and cladribine for HCL and their comparison
10:30 Michael Grever, MD: Current uses of pentostatin and new ideas in the management of HCL
10:45–11:15 BREAK & POSTERS

Treatment of HCL with Cladribine
11:15 Alan Saven, MD: Development of cladribine at Scripps for HCL and current results
11:30 Pier Luigi Zinzani, MD: Cladribine treatment for HCL in Europe
11:45 Francesco Lauria, MD: Investigation of alternate methods of cladribine administration
12:00 James Johnston, MD: Sensitivity to purine analogs cladribine and pentostatin and patterns of response
12:15 Gunnar Juliussen, MD: Pharmacokinetics of purine analogs and other treatments for HCL
12:30 Discussion
12:40–1:30 LUNCH & POSTERS

Toxicity of Purine Analogs
1:30 Eric Kraut, MD: Infections with HCL and purine analogs
1:45 Tamar Tadmor, MD: Inherent toxicity of purine analogs to the immune system and stem cells

(Continued on next page)
Uncommon Problems in HCL
2:00  Tadeusz Robak, MD, PhD: Management of HCL variant
2:15  Aaron Polliack, MD: Unusual Manifestations of HCL

Implications of Minimal Residual Disease (MRD) in HCL
2:30  Pierre Noel, MD: CR with and without MRD: Criteria by bone marrow immunohistochemistry
2:45  Martin Tallman, MD: Clinical data from cladribine testing using immunohistochemistry
3:00  Mark Raffeld, MD: High-sensitivity PCR tests for HCL MRD
3:15  John Janik, MD: Tumor markers in HCL

3:30–3:45 BREAK & POSTERS

Treatment of HCL with Rituximab
3:45  Deborah Thomas, MD: Rituximab as a single agent for HCL, mechanisms of action and results
4:00  Farhad Ravandi, MD: Rituximab combined with cladribine for HCL
4:15  Jeffrey Jorgensen, MD, PhD: Minimal residual disease after cladribine and rituximab
4:30  Monica Else, MA: Rituximab combined with pentostatin or cladribine for HCL
4:45 Discussion

Monday night dinner for invited speakers and guests
6:30 Cocktails, 7:30 Dinner (Bethesda Marriott, 5151 Pooks Hill Rd, Bethesda, MD 20814)

Tuesday April 27, 2010
7:15 Posters and Continental Breakfast

Recombinant Immunotoxin Treatment of HCL
8:00  David FitzGerald, PhD: Development and mechanism of action of recombinant immunotoxins
8:15  Robert Kreitman, MD: Recombinant immunotoxins in HCL
8:30  Ira Pastan, MD: Immunotoxins with decreased immunogenicity and improved activity

Into the Future: New Agents and Targets
8:45  James Paulson, PhD: Targeting B cell lymphoma with nanoparticles bearing glycan ligands of CD22
9:05  Wyndham Wilson, MD, PhD: Biomarkers in lymphoma
9:20 Discussion

Transplantation for HCL
9:40  Steven Pavletic, MD: Exploiting allogeneic graft-versus malignancy in HCL & other lymphoid malignancies
9:55-10:45  Break, Posters, and Group Picture

HCL Biology
10:45  John Cawley, MD, PhD: Hairy cell interactions with the microenvironment
11:00  Jan Burger, MD, PhD: Interactions between the microenvironment and CLL. Implications for HCL
11:15  Emili Montserrat, MD, PhD: Mechanisms of cell death from therapy for HCL and CLL

Molecular Characterization of HCL
11:30  Evgeny Arons, PhD: Molecular variant of HCL with poor prognosis
11:45  Francesco Forconi, MD, PhD: Molecular insight into the behavior of HCL by immunogenetic analysis

Patient Point of View: Research and Patient Access to Information and Trials
12:00  Earl Stone: The patient’s point of view, from the President of the HCL Research Foundation
12:15  Michael Grever, MD: Development and goals of the HCL Consortium

For more information or to register, please visit http://web.ncifcrf.gov/events/leukemia/default.asp